Maria-Cristina de C Brandileone1, Rosemeire C Zanella2, Samanta C G Almeida3, Ana Paula Cassiolato4, Ana Paula S de Lemos5, Maristela M Salgado6, Fábio T Higa7, Ruth Minamisava8, Ana Lucia Andrade9. 1. National Laboratory for Meningitis and Pneumococcal Infections, Laboratory for Meningitis, Pneumonia and Pneumococcal Infection, Center of Bacteriology, Brazil. Electronic address: maria.brandileone@ial.sp.gov.br. 2. National Laboratory for Meningitis and Pneumococcal Infections, Laboratory for Meningitis, Pneumonia and Pneumococcal Infection, Center of Bacteriology, Brazil. Electronic address: rosemeire.zanella@ial.sp.gov.br. 3. National Laboratory for Meningitis and Pneumococcal Infections, Laboratory for Meningitis, Pneumonia and Pneumococcal Infection, Center of Bacteriology, Brazil. Electronic address: samanta.almeida@ial.sp.gov.br. 4. National Laboratory for Meningitis and Pneumococcal Infections, Laboratory for Meningitis, Pneumonia and Pneumococcal Infection, Center of Bacteriology, Brazil. 5. National Laboratory for Meningitis and Pneumococcal Infections, Laboratory for Meningitis, Pneumonia and Pneumococcal Infection, Center of Bacteriology, Brazil. Electronic address: ana.lemos@ial.sp.gov.br. 6. Molecular Biology Laboratory, Center of Immunology, Institute Adolfo Lutz (IAL), São Paulo, State of São Paulo, Brazil. Electronic address: maristela.salgado@ial.sp.gov.br. 7. Molecular Biology Laboratory, Center of Immunology, Institute Adolfo Lutz (IAL), São Paulo, State of São Paulo, Brazil. Electronic address: fabio.higa@ial.sp.gov.br. 8. Faculty of Nursing, Federal University of Goiás, Goiânia, State of Goiás, Brazil. 9. Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia, State of Goiás, Brazil.
Abstract
Brazil introduced the 10-valent pneumococcal vaccine (PCV10) to the routine national immunization program (NIP) in March 2010. In 2017, we investigated the effects of PCV10 on nasopharyngeal carriage of vaccine-types (VT) and non-vaccine-types (NVT) of Streptococcus pneumoniae (Spn) among children living in São Paulo city. We also compared the prevalence of VT and NVT with previous carriage surveys performed in 2010 (baseline) and 2013. METHOD: The carriage survey was conducted among 531 children, aged 12 months to <24 months, recruited from public Primary Health Units during the immunization campaign, using previous surveys methodology, except for qPCR, which was performed in the 2017 survey only. RESULTS: No statistical difference was found in the prevalence of Spn either by culture (59.7%) or by qPCR (61.2%). Spn carriage increased from 40.3% (baseline) to 59.7% (2017 survey) (p < 0.001). Colonization by VT isolates significantly decreased by 90.9% (19.8-1.8%) and 95.5% (19.8-0.9%) in the 2013 and 2017 surveys, respectively, compared to that at baseline. NVT isolates increased significantly by 128% (19.6-44.8%) and 185% (19.6-55.9%) in the respective post-PCV10 surveys, most led to high prevalence of serotypes 6C (27%), 15B (9.8%), 19A (9.2%), 15A (6.0%), and 16F (5.7%). In 2017, reduction in serotype 6A (4.2-0.6%, p < 0.001) and increase in serotype 19A (1.8-6.0%, p = 0.001) were found; serotype 3 isolate was not detected in the present survey. We identified the emergence of 19A isolates CC320, associated with high penicillin (MIC ≥ 2.0 mg/L) and cefotaxime (MIC ≥ 1.0 mg/L) values. CONCLUSION: After 7 years of PCV10 introduction in the NIP, colonization by VT among toddlers decreased substantially to a residual level, along with substantial serotype replacement by novel serotypes not present in any current conjugated pneumococcal vaccine and serotype 19A. The present findings can assist policy decisions in Brazil.
Brazil introduced the 10-valent pneumococcal vaccine (PCV10) to the routine national immunization program (NIP) in March 2010. In 2017, we investigated the effects of PCV10 on nasopharyngeal carriage of vaccine-types (VT) and non-vaccine-types (NVT) of Streptococcus pneumoniae (Spn) among children living in São Paulo city. We also compared the prevalence of VT and NVT with previous carriage surveys performed in 2010 (baseline) and 2013. METHOD: The carriage survey was conducted among 531 children, aged 12 months to <24 months, recruited from public Primary Health Units during the immunization campaign, using previous surveys methodology, except for qPCR, which was performed in the 2017 survey only. RESULTS: No statistical difference was found in the prevalence of Spn either by culture (59.7%) or by qPCR (61.2%). Spn carriage increased from 40.3% (baseline) to 59.7% (2017 survey) (p < 0.001). Colonization by VT isolates significantly decreased by 90.9% (19.8-1.8%) and 95.5% (19.8-0.9%) in the 2013 and 2017 surveys, respectively, compared to that at baseline. NVT isolates increased significantly by 128% (19.6-44.8%) and 185% (19.6-55.9%) in the respective post-PCV10 surveys, most led to high prevalence of serotypes 6C (27%), 15B (9.8%), 19A (9.2%), 15A (6.0%), and 16F (5.7%). In 2017, reduction in serotype 6A (4.2-0.6%, p < 0.001) and increase in serotype 19A (1.8-6.0%, p = 0.001) were found; serotype 3 isolate was not detected in the present survey. We identified the emergence of 19A isolates CC320, associated with high penicillin (MIC ≥ 2.0 mg/L) and cefotaxime (MIC ≥ 1.0 mg/L) values. CONCLUSION: After 7 years of PCV10 introduction in the NIP, colonization by VT among toddlers decreased substantially to a residual level, along with substantial serotype replacement by novel serotypes not present in any current conjugated pneumococcal vaccine and serotype 19A. The present findings can assist policy decisions in Brazil.
Authors: Adriana Weinberg; Petronella Muresan; Lauren Laimon; Stephen I Pelton; David Goldblatt; Jennifer Canniff; Bonnie Zimmer; Frederic Bone; Lassallete Newton; Terence Fenton; James Kiely; Michael J Johnson; Esau C Joao; Breno R Santos; Elizabeth S Machado; Jorge A Pinto; Nahida Chakhtoura; Geraldo Duarte; Marisa M Mussi-Pinhata Journal: Lancet HIV Date: 2021-04-27 Impact factor: 16.070
Authors: Maria L Moura; Icaro Boszczowski; Manuela Blaque; Rafael M Mussarelli; Victor Fossaluza; Ligia C Pierrotti; Gustavo Campana; Maria C Brandileone; Rosemeire Zanella; Samanta C G Almeida; Anna S Levin Journal: Emerg Infect Dis Date: 2022-01 Impact factor: 6.883
Authors: Bruna M S Seco; Fei-Fei Xu; Andrea Grafmüller; Naresh Kottari; Claney L Pereira; Peter H Seeberger Journal: ACS Chem Biol Date: 2020-09-08 Impact factor: 5.100
Authors: Samanta C G Almeida; Stephanie W Lo; Paulina A Hawkins; Rebecca A Gladstone; Ana Paula Cassiolato; Keith P Klugman; Robert F Breiman; Stephen D Bentley; Lesley McGee; Maria-Cristina de C Brandileone Journal: Microb Genom Date: 2021-10